Reston, VA (July 17, 2026)— New research has been published ahead-of-print by The Journal of Nuclear Medicine ( JNM ). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Targeted Radiation and PARP Inhibitor Show Promise Against Pancreatic Cancer
Researchers evaluated a targeted treatment combining the radiopharmaceutical 177 Lu-DOTA-ABM-5G with the PARP inhibitor olaparib for pancreatic cancer. Laboratory and animal studies found the therapy reached tumors, reduced cancer cell growth, increased DNA damage, slowed tumor progression, and extended survival compared with either treatment alone.
New PET-Based Score May Help Predict Outcomes Before Prostate Cancer Therapy
Researchers developed and validated the PROFILE score, which combines findings from two PET scans with routine clinical measures to estimate survival in patients with advanced prostate cancer before targeted radiopharmaceutical therapy. The score classified patients into low-, intermediate-, and high-risk groups across independent patient cohorts.
Study Explores Blood Cell Mutations in Patients Receiving Targeted Prostate Cancer Therapy
Researchers examined clonal hematopoiesis—age-related blood cell mutations—in patients receiving 177 Lu PSMA therapy for advanced prostate cancer. While overall survival was similar regardless of mutation status, patients with these mutations showed a trend toward greater blood-related side effects, and new or expanding mutations were commonly observed during treatment.
Tau PET Scan Detects Early Alzheimer’s-Related Brain Changes in Healthy Older Adults
Researchers found that a second-generation tau PET imaging tracer detected brain changes linked to Alzheimer’s disease risk in cognitively healthy older adults. Higher tracer uptake was associated with female sex, genetic risk, a blood biomarker of Alzheimer’s disease, and poorer episodic memory, suggesting potential for identifying early disease-related changes.
Visit the JNM website for the latest research and follow our Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org .
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 90 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
Journal of Nuclear Medicine